These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 28222016)

  • 21. Standardisation of molecular monitoring for chronic myeloid leukaemia.
    Cross NC
    Best Pract Res Clin Haematol; 2009 Sep; 22(3):355-65. PubMed ID: 19959086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of a novel multiplex RT-qPCR assay for the quantification of leukemia-associated BCR-ABL1 translocation.
    Kottwitz D; El Hadi H; El Amrani M; Cabezas S; Dehbi H; Nadifi S; Quessar A; Colomer D; Moumen A; Sefrioui EL
    Int J Hematol; 2015 Sep; 102(3):335-41. PubMed ID: 26243622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA.
    White HE; Matejtschuk P; Rigsby P; Gabert J; Lin F; Lynn Wang Y; Branford S; Müller MC; Beaufils N; Beillard E; Colomer D; Dvorakova D; Ehrencrona H; Goh HG; El Housni H; Jones D; Kairisto V; Kamel-Reid S; Kim DW; Langabeer S; Ma ES; Press RD; Romeo G; Wang L; Zoi K; Hughes T; Saglio G; Hochhaus A; Goldman JM; Metcalfe P; Cross NC
    Blood; 2010 Nov; 116(22):e111-7. PubMed ID: 20720184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative BCR-ABL1 RQ-PCR fusion transcript monitoring in chronic myelogenous leukemia.
    Moore FR; Rempfer CB; Press RD
    Methods Mol Biol; 2013; 999():1-23. PubMed ID: 23666687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytogenetic, fluorescence in situ hybridization, and genomic array characterization of chronic myeloid leukemia with cryptic BCR-ABL1 fusions.
    Shao L; Miller S; Keller-Ramey J; Zhang Y; Roulston D
    Cancer Genet; 2015; 208(7-8):396-403. PubMed ID: 26186983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan.
    Yoshida C; Fletcher L; Ohashi K; Wakita H; Kumagai T; Shiseki M; Matsuei K; Inokuchi K; Hatta Y; Shirasugi Y; Yamaguchi T; Sakamoto J; Branford S; Sakamaki H
    Int J Clin Oncol; 2012 Dec; 17(6):584-9. PubMed ID: 21986632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. One-Step Multiplexed Droplet Digital Polymerase Chain Reaction for Quantification of p190 BCR-ABL1 Fusion Transcript in B-Lymphoblastic Leukemia.
    Martinez RJ; Kang Q; Nennig D; Bailey NG; Brown NA; Betz BL; Tewari M; Thyagarajan B; Bachanova V; Mroz P
    Arch Pathol Lab Med; 2022 Jan; 146(1):92-100. PubMed ID: 33769465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia.
    García-Gutiérrez V; Gómez-Casares MT; Puerta JM; Alonso-Domínguez JM; Osorio S; Hernández-Boluda JC; Collado R; Ramírez MJ; Ibáñez F; Martín ML; Rodríguez-Gambarte JD; Martínez-Laperche C; Gómez M; Fiallo DV; Redondo S; Rodríguez A; Ruiz-Nuño C; Steegmann JL; Jiménez-Velasco A;
    PLoS One; 2017; 12(3):e0173532. PubMed ID: 28278193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. External quality assessment of p210 BCR-ABL1 transcript quantification by RT-qPCR: Findings and recommendations.
    Fu Y; Zhang R; Wu Q; Zhang J; Bao L; Li J
    Int J Lab Hematol; 2019 Feb; 41(1):46-54. PubMed ID: 30203581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK.
    Cross NCP; White HE; Evans PAS; Hancock J; Copland M; Milojkovic D; Mason J; Craine S; Mead AJ
    Br J Haematol; 2018 Sep; 182(6):777-788. PubMed ID: 30125955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Molecular analysis of the BCR-ABL1 fusion gene in a chronic myeloid leukemia patient with BCR-ABL1 International Scale-undetectable disease].
    Kawamata N; Watanabe R
    Rinsho Ketsueki; 2019; 60(7):767-772. PubMed ID: 31391364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Calibration of BCR-ABL1 mRNA quantification methods using genetic reference materials is a valid strategy to report results on the international scale.
    Mauté C; Nibourel O; Réa D; Coiteux V; Grardel N; Preudhomme C; Cayuela JM;
    Clin Biochem; 2014 Sep; 47(13-14):1333-6. PubMed ID: 24915631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measurement of BCR-ABL1 by RT-qPCR in chronic myeloid leukaemia: findings from an International EQA Programme.
    Scott S; Travis D; Whitby L; Bainbridge J; Cross NCP; Barnett D
    Br J Haematol; 2017 May; 177(3):414-422. PubMed ID: 28295199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quality control methods for optimal BCR-ABL1 clinical testing in human whole blood samples.
    Stanoszek LM; Crawford EL; Blomquist TM; Warns JA; Willey PF; Willey JC
    J Mol Diagn; 2013 May; 15(3):391-400. PubMed ID: 23541592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of droplet digital polymerase chain reaction for measuring BCR-ABL1 in chronic myeloid leukaemia in an international interlaboratory study.
    Scott S; Cartwright A; Francis S; Whitby L; Sanzone AP; Mulder A; Galimberti S; Dulucq S; Mauté C; Lauricella C; Salmon M; Rose S; Willoughby J; Boeckx N; Pallisgaard N; Maier J; Leibundgut EO; Zizkova H; Ling Goh L; Duong C; Tang WF; Ma E; Shivakumar Y; Beppu L; Bhagavatula P; Chantry A
    Br J Haematol; 2021 Jul; 194(1):53-60. PubMed ID: 34114218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BCR-ABL1 RT-qPCR for monitoring the molecular response to tyrosine kinase inhibitors in chronic myeloid leukemia.
    Press RD; Kamel-Reid S; Ang D
    J Mol Diagn; 2013 Sep; 15(5):565-76. PubMed ID: 23810242
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparison of quantitative detection of BCR::ABL1 p210 transcript levels: a multicenter study].
    Zhao CT; Ni CR; Lin YN; Ma XL; Wu QS; Wang F; Han XX; Liu F; Xu Y; Liu HX; Chen J; Ru K; Zhu MH
    Zhonghua Bing Li Xue Za Zhi; 2024 Jul; 53(7):672-677. PubMed ID: 38955697
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of Droplet Digital PCR versus qPCR Measurements on the International Scale for the Molecular Monitoring of Chronic Myeloid Leukemia Patients.
    Cortés AA; Olmedillas S; Serrano-López J; Lainez-González D; Castaño T; Iñiguez R; Lopez-Lorenzo JL; García A; Atance M; Sánchez RNS; Lopez CB; Arranz MG; Sillero PL; Alonso-Dominguez JM
    Mol Diagn Ther; 2020 Oct; 24(5):593-600. PubMed ID: 32875515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BCR-ABL1 p210 screening for chronic myeloid leukemia in patients with peripheral blood cytoses.
    Fenu E; O'Neill SS; Insuasti-Beltran G
    Int J Lab Hematol; 2021 Dec; 43(6):1458-1464. PubMed ID: 34185393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study.
    White HE; Salmon M; Albano F; Andersen CSA; Balabanov S; Balatzenko G; Barbany G; Cayuela JM; Cerveira N; Cochaux P; Colomer D; Coriu D; Diamond J; Dietz C; Dulucq S; Engvall M; Franke GN; Gineikiene-Valentine E; Gniot M; Gómez-Casares MT; Gottardi E; Hayden C; Hayette S; Hedblom A; Ilea A; Izzo B; Jiménez-Velasco A; Jurcek T; Kairisto V; Langabeer SE; Lion T; Meggyesi N; Mešanović S; Mihok L; Mitterbauer-Hohendanner G; Moeckel S; Naumann N; Nibourel O; Oppliger Leibundgut E; Panayiotidis P; Podgornik H; Pott C; Rapado I; Rose SJ; Schäfer V; Touloumenidou T; Veigaard C; Venniker-Punt B; Venturi C; Vigneri P; Vorkinn I; Wilkinson E; Zadro R; Zawada M; Zizkova H; Müller MC; Saussele S; Ernst T; Machova Polakova K; Hochhaus A; Cross NCP
    Leukemia; 2022 Jul; 36(7):1834-1842. PubMed ID: 35614319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.